Evaluating Biologics for Chronic Rhinosinusitis with Nasal Polyps
Real-life Evaluation of the Efficacy of Biologicals in Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)
Recruiting
Observational Study
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Chronic Rhinosinusitis (CRS)
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 300 (estimated)
- Sponsor
- Universitaire Ziekenhuizen KU Leuven · Other
Who this trial is looking for
This trial is looking for adults with chronic rhinosinusitis and nasal polyps who are eligible for certain biological treatments. Participants will provide feedback on their health and symptoms over a 24-week period.
Are You a Good Fit for This Trial?
You may be able to join if
- I am at least 18 years old.
- I can give informed consent.
- I have chronic rhinosinusitis with nasal polyps.
- I meet the criteria for reimbursement of a biological treatment.
You may not be able to join if
- I have received other biological therapies in the last 3 months.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this observational study is to learn more about the real-world efficacy of biologics in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP). All patients who are 18 years or older, who have CRSwNP and are eligible for reimbursement of a biological for the indication of CRSwNP can be included.
The main question is the efficacy of biologics in real life after 24 weeks. Th…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Participant must be at least 18 years of age at the time of signing the informed consent.
2. Capable of giving signed informed consent.
3. Participants should have CRSwNP.
4. Participants should fulfil the reimbursement criteria for their prescribed biological (omalizumab, me…
Contacts